Twenty-five years: The fexofenadine clinical experience

IF 3.9 2区医学 Q2 ALLERGY World Allergy Organization Journal Pub Date : 2024-08-20 DOI:10.1016/j.waojou.2024.100950

Robert M. Naclerio MD , Ignacio J. Ansotegui MD, PhD , Giorgio Walter Canonica MD , Philip Rouadi MD , Luo Zhang MD , Margarita Murrieta-Aguttes MD

{"title":"Twenty-five years: The fexofenadine clinical experience","authors":"Robert M. Naclerio MD , Ignacio J. Ansotegui MD, PhD , Giorgio Walter Canonica MD , Philip Rouadi MD , Luo Zhang MD , Margarita Murrieta-Aguttes MD","doi":"10.1016/j.waojou.2024.100950","DOIUrl":null,"url":null,"abstract":"<div>Allergic rhinitis (AR) and urticaria affect a sizable portion of the population worldwide, resulting in reduced quality-of-life and productivity and increased healthcare costs.Fexofenadine (FEX) is a non-sedating second-generation H1 antihistamine with pronounced efficacy and a very good safety profile, used for the treatment of allergic diseases. In addition to its antihistaminic properties, FEX also has anti-inflammatory effects. FEX has a wide therapeutic window and is not associated with any sedative effects, even at higher than recommended doses.There is a need for an integrated management system for AR and urticaria which includes safe and effective treatment options.An ideal anti-allergic formulation should provide fast relief of symptoms and long-lasting effect without drowsiness. Data from randomized clinical trials show that FEX meets these criteria and is an effective treatment option with a favourable safety profile, improving the quality of life of patients suffering from AR and urticaria.</div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100950"},"PeriodicalIF":3.9000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000814/pdfft?md5=d0f1209e11de86cb11795e4af2081d21&pid=1-s2.0-S1939455124000814-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Allergy Organization Journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1939455124000814","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Allergic rhinitis (AR) and urticaria affect a sizable portion of the population worldwide, resulting in reduced quality-of-life and productivity and increased healthcare costs.

Fexofenadine (FEX) is a non-sedating second-generation H₁ antihistamine with pronounced efficacy and a very good safety profile, used for the treatment of allergic diseases. In addition to its antihistaminic properties, FEX also has anti-inflammatory effects. FEX has a wide therapeutic window and is not associated with any sedative effects, even at higher than recommended doses.

There is a need for an integrated management system for AR and urticaria which includes safe and effective treatment options.

An ideal anti-allergic formulation should provide fast relief of symptoms and long-lasting effect without drowsiness. Data from randomized clinical trials show that FEX meets these criteria and is an effective treatment option with a favourable safety profile, improving the quality of life of patients suffering from AR and urticaria.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

二十五年非索非那定临床经验

过敏性鼻炎（AR）和荨麻疹影响着全球相当一部分人口，导致生活质量和工作效率下降，医疗费用增加。非索非那定（FEX）是一种非镇静型第二代 H1 抗组胺药，具有明显的疗效和良好的安全性，用于治疗过敏性疾病。除抗组胺特性外，FEX 还具有抗炎作用。理想的抗过敏制剂应能快速缓解症状，疗效持久，且无嗜睡症状。随机临床试验的数据显示，FEX 符合这些标准，是一种安全性良好的有效治疗方案，可改善 AR 和荨麻疹患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

World Allergy Organization Journal Immunology and Microbiology-Immunology

CiteScore

9.10

自引率

5.90%

发文量

审稿时长

9 weeks

期刊介绍： The official pubication of the World Allergy Organization, the World Allergy Organization Journal (WAOjournal) publishes original mechanistic, translational, and clinical research on the topics of allergy, asthma, anaphylaxis, and clincial immunology, as well as reviews, guidelines, and position papers that contribute to the improvement of patient care. WAOjournal publishes research on the growth of allergy prevalence within the scope of single countries, country comparisons, and practical global issues and regulations, or threats to the allergy specialty. The Journal invites the submissions of all authors interested in publishing on current global problems in allergy, asthma, anaphylaxis, and immunology. Of particular interest are the immunological consequences of climate change and the subsequent systematic transformations in food habits and their consequences for the allergy/immunology discipline.